X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Content Team by Content Team
17th January 2022
in News
As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to the forecast shared by WHO top officials more than half of Europe will suffer from the highly contagious variant of COVID-19, Omicron in the next couple of months. As per one of the top line directors at WHO, there is a sweep of the west to east tidal wave of infection of Omicron which in the region over and above the pre-existent delta variant.

The variant is dominantly stamping its spread across the west of Europe and is now charging towards the Balkans. The region has already seen above 7 million patients in the first week of this year. This figure is double to the two-week prior period. With the rate things are moving, the health metrics and evaluation institute predict that more than half of the regional population will be under the clutches of omicron and that too in the next 6-8 weeks.

The variant has swept the entire region at a brisk pace and countries, big or small, developed or developing are already introducing various social restrictions to curb its unwanted expanse. All the shreds of evidence however suggest that the omicron is less lethal than the delta variant but the sheer numbers are enough to overwhelm the health care system. One of the professors at Oxford believes that omicron is not the same virus as its predecessors and the horrific scenes that all had to go through of people succumbing prematurely, hospitals overflowing with admissions is history.

As far as the disease is concerned, the variant seems to be less impactful with many people being hospitalized for a less period of time. Oxygen high flow isn’t the need with an average stay of patients being three days max. The fact is that the places where COVID incident rates have been higher tagged with low vaccination turnouts, the mortality rate is stable.

Previous Post

Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Next Post

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In